GLP1 News and Research

RSS

Tirzepatide outperforms insulin in controlling diabetes and promoting weight loss in clinical trials

Tirzepatide, a once-weekly dual agonist, outperforms long-acting insulin in reducing HbA1c, body weight, and improving cardiovascular markers in Type 2 diabetes patients.

2 Sep 2024

ESC consensus statement highlights obesity's impact on cardiovascular disease

The ESC Clinical Consensus Statement on Obesity and Cardiovascular Disease, presented at this year's ESC Congress (London, UK, 30 August to 2 September) summarizes current evidence on the epidemiology and etiology of obesity; the interplay between obesity, cardiovascular risk factors and cardiac conditions; the clinical management of patients with cardiac disease and obesity; and weight loss strategies including lifestyle changes, interventional procedures, and anti-obesity medications with particular focus on their impact on cardiometabolic risk and cardiac outcomes.

30 Aug 2024

Tirzepatide beats semaglutide in lowering diabetes risk and cardiovascular events in obesity patients

A study published in eClinicalMedicine found that tirzepatide outperforms semaglutide in reducing the risk of type 2 diabetes and major cardiovascular events among individuals with obesity, with or without existing diabetes, while also achieving greater weight loss.

28 Aug 2024

Study finds potential for antidiabetic drugs to modify osteoarthritis risk

Whether antidiabetic medications could potentially be used as disease-modifying osteoarthritis drugs or DMOADs for the therapeutic management of osteoarthritis.

21 Aug 2024

$Study reveals obesity's impact on muscle structure in heart failure with preserved ejection fraction$

Study reveals obesity's impact on muscle structure in heart failure with preserved ejection fraction

A new small study led by Johns Hopkins Medicine researchers and published July 25th in the journal Nature Cardiovascular Research has revealed the impact of obesity on muscle structure in patients having a form of heart failure called heart failure with a preserved ejection fraction (HFpEF).

1 Aug 2024

Why millions are trying FDA-authorized alternatives to big pharma’s weight loss drugs

Pharmacist Mark Mikhael has lost 50 pounds over the past 12 months. He no longer has diabetes and finds himself "at my ideal body weight," with his cholesterol below 200 for the first time in 20 years. "I feel fantastic," he said.

23 Jul 2024

Study identifies trends in the use of glucagon-like peptide-1 receptor agonists

Investigators at Cedars-Sinai and other institutions conducted a nationwide, population-based study to identify trends in the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs)-;prescription medications sold under popular drug names like Ozempic and Wegovy-;in the United States.

22 Jul 2024

Semaglutide shows no higher 12-month risk of adverse neuropsychiatric outcomes than other antidiabetic drugs, study suggests

Researchers evaluated the 12-month neurological and psychiatric outcomes of semaglutide use in patients with type 2 diabetes mellitus using a propensity-score matched cohort.

17 Jul 2024

Twincretin drug Tirzepatide shows unmatched efficacy in weight loss and diabetes management

Tirzepatide, a novel twincretin drug, significantly improves weight loss and glycemic control in obese and type 2 diabetes patients, outperforming traditional treatments in clinical trials.

15 Jul 2024

New brain targets for GLP1-based obesity drugs may reduce weight without nausea

Researchers identified distinct hindbrain GLP1R neurons driving satiety and aversion, offering new targets for effective, side-effect-free obesity treatments.

14 Jul 2024

Combined use of popular diabetes drugs likely to offer additional protection against heart and kidney disease

New research shows combined use of sodium glucose co-transporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP1-RAs) is likely to offer additional protection against heart and kidney disease in patients with diabetes.

8 Jul 2024

Novo Nordisk presents key findings from semaglutide trials at ADA scientific sessions 2024

Novo Nordisk today announced the presentation of 34 abstracts highlighting the breadth of its portfolio at the upcoming 84th Scientific Sessions of the American Diabetes Association (ADA).

22 Jun 2024

Wegovy and Ozempic linked to reduced incidence and recurrence of alcohol abuse or dependence, study suggests

Researchers investigated the potential therapeutic benefits of semaglutide for alcohol use disorders.

14 Jun 2024

AI-based analysis uncovers two plant extracts with potential as GLP-1 agonist weight loss pills

Two plant compounds with potential as GLP-1 agonist weight loss pills have been identified in an AI (artificial intelligence)-based study, the European Congress on Obesity (ECO 2024) (Venice 12-15 May), will hear.

26 Mar 2024

SGLT2 inhibitors linked to lower risk of kidney stones in patients with type 2 diabetes

Rates of kidney stones are on the rise in the United States and around the world. Type 2 diabetes is associated with increased risk of kidney stones, but some forms of treatment for this condition may also have the benefit of lowering risk of kidney stones.

31 Jan 2024

Study links GLP1 agonists to reduced risk of severe liver disease in diabetic patients

Ozempic and other GLP1 agonists are associated with a reduced risk of developing cirrhosis and liver cancer in people with type 2 diabetes and chronic liver disease, according to a nationwide study from Karolinska Institutet in Sweden published in the journal Gut.

23 Jan 2024

GLP1 News and Research

Tirzepatide outperforms insulin in controlling diabetes and promoting weight loss in clinical trials

ESC consensus statement highlights obesity's impact on cardiovascular disease

Tirzepatide beats semaglutide in lowering diabetes risk and cardiovascular events in obesity patients

Study finds potential for antidiabetic drugs to modify osteoarthritis risk

Study reveals obesity's impact on muscle structure in heart failure with preserved ejection fraction

Why millions are trying FDA-authorized alternatives to big pharma’s weight loss drugs

Study identifies trends in the use of glucagon-like peptide-1 receptor agonists

Semaglutide shows no higher 12-month risk of adverse neuropsychiatric outcomes than other antidiabetic drugs, study suggests

Twincretin drug Tirzepatide shows unmatched efficacy in weight loss and diabetes management

New brain targets for GLP1-based obesity drugs may reduce weight without nausea

Combined use of popular diabetes drugs likely to offer additional protection against heart and kidney disease

Novo Nordisk presents key findings from semaglutide trials at ADA scientific sessions 2024

Wegovy and Ozempic linked to reduced incidence and recurrence of alcohol abuse or dependence, study suggests

AI-based analysis uncovers two plant extracts with potential as GLP-1 agonist weight loss pills

SGLT2 inhibitors linked to lower risk of kidney stones in patients with type 2 diabetes

Study links GLP1 agonists to reduced risk of severe liver disease in diabetic patients

From diabetes drug to anti-inflammation powerhouse: The unexpected evolution of GLP-1

How safe are GLP-1R agonists in early pregnancy?

New insights into how anti-obesity drugs could help prevent kidney disease

New study links DNA methylation in GLP1R gene to obesity without metabolic disorders

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News